

Area Prescribing Group report

Date: Friday 01 March 2024 **Quorate:** Yes

The items in this report are supported by the area prescribing group and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

Document links provided for any APG recommendations are temporarily hosted on the legacy Pan Mersey APC website as a pragmatic solution until such time as a Cheshire and Merseyside APG website is available. The [legacy Cheshire formulary](#) will also be updated to reflect these changes.

CMAPG governance documents are now hosted on the new [Prescribing](#) section of the NHS Cheshire and Merseyside website, which is currently being developed

New medicines other

Proposal	Notes	Approval
<p>Risankizumab for Crohn's disease</p> <p>RAG designation: Red</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>Minor update to remove formulations from document.</p> <p>NMSG felt that the existing statement may be interpreted to preclude use of the 600mg infusion for the induction regime, which was not the intention.</p> <p>Formulations will be included in the formulary instead. This aligns with the proposed new format of the prescribing statements which does not include the formulation in the title of the document.</p>	<p>MOP: 21 March 2024, approved by ICB Medicines Optimisation and Pharmacy Group.</p>

Proposal	Notes	Approval
<p>Tirzepatide for type 2 diabetes</p> <p>RAG designation: Green</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>Minor update to remove references to use with insulin from the document.</p> <p>There are references to use with insulin included in the statement which may cause confusion. The aim of the statement is to promote use in line with NICE TA924, which does not extend to use with insulin.</p>	<p>MOP: 21 March 2024, approved by ICB Medicines Optimisation and Pharmacy Group.</p>
<p>Cytisine for smoking cessation</p> <p>RAG designation: Grey</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>For noting.</p> <p>A grey RAG has been assigned pending review by the NMSG.</p>	<p>MOP: 21 March 2024, noted by ICB Medicines Optimisation and Pharmacy Group.</p>
<p>Fezolinetant for vasomotor symptoms associated with menopause</p> <p>RAG designation: Grey</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>For noting.</p> <p>For noting. A grey RAG has been assigned pending publication of the NICE TA.</p>	<p>MOP: 21 March 2024, noted by ICB Medicines Optimisation and Pharmacy Group.</p>
<p>Lebrikizumab for atopic dermatitis</p> <p>RAG designation: Grey</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>For noting.</p> <p>For noting. A grey RAG has been assigned pending publication of the NICE TA.</p>	<p>MOP: 21 March 2024, noted by ICB Medicines Optimisation and Pharmacy Group.</p>

Proposal	Notes	Approval
<p>Ritlectinib for alopecia areata</p> <p>RAG designation: Grey</p> <p>APG subgroup: 09 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>For noting.</p> <p>For noting. A grey RAG has been assigned pending publication of the NICE TA.</p>	<p>MOP: 21 March 2024, noted by ICB Medicines Optimisation and Pharmacy Group.</p>

Formulary and guidelines

Proposal	Notes	Approval
<p>Formulary amendment - addition of Trurapi® brand biosimilar insulin aspart for Merseyside patients.</p> <p>RAG designation: Amber initiated in Merseyside, green in Cheshire – pending the rapid harmonisation of formulary chapter 6.</p> <p>APG subgroup: 20 Feb 2024</p> <p>APG: 01 Mar 2024</p>	<p>Use of Trurapi® instead of Novorapid® will achieve significant savings across Cheshire and Merseyside. There are 16,000 eligible patients and the savings are in the region of 40% and amendment of the formulary as above will support cost-saving initiatives.</p>	<p>MOP: 21 March 2024, approved by ICB Medicines Optimisation and Pharmacy Group.</p>

Safety

Proposal	Notes	Approval
CLOZAPINE: reducing the risk of harm RAG designation: not applicable APG subgroup: 17 Jan 2024 APG: 01 Mar 2024	Minor update to the antibiotic drug interaction table header. Amended to: "...increase or decrease serum clozapine..." as the list includes rifampicin which is an enzyme inducer.	MOP: 21 March 2024, approved by ICB Medicines Optimisation and Pharmacy Group.

APG reports

Proposal	Notes	Approval
NICE TA adherence checklist January 2024	For noting	MOP: 21 March 2024, noted by ICB Medicines Optimisation and Pharmacy Group.